The blockade of CSF-1/CSF-1R activation can be a promising approach in pancreatic cancer therapy via reducing the TAM population, using combinative partners of standard treatment and immunotherapeutic agents (Cannarile et al., 2017). This evidence concerns the gene CSF1 and pancreatic neoplasm.